Craft

Leap Therapeutics

Stock Price

$1.9

2024-06-18

Market Capitalization

$74.2 M

2024-06-18

Revenue

$1.5 M

FY, 2021

Leap Therapeutics Summary

Company Summary

Overview
Leap Therapeutics (formerly known as HealthCare Pharmaceuticals) is a biopharmaceutical company developing targeted and immuno-oncology therapeutics. It offers DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 protein; FL-301, a humanized monoclonal antibody targeting Claudin18.2; and other antibody programs targeting Claudin18.2/CD137 and GDF15.
Type
Public
Status
Active
Founded
2011
HQ
Cambridge, MA, US | view all locations
Website
https://www.leaptx.com
Cybersecurity rating
Sectors

Key People

  • Douglas Onsi

    Douglas Onsi, President, CEO & Director

  • Mark O'Mahony

    Mark O'Mahony, Chief Manufacturing Officer

  • Gus Lawlor

    Gus Lawlor, Chief Operating Officer

  • Jason Baum

    Jason Baum, Chief Scientific Officer

LocationsView all

1 location detected

  • Cambridge, MA HQ

    United States

    47 Thorndike St B1-1

Leap Therapeutics Financials

Summary Financials

Net income (Q1, 2024)
($13.8M)
Cash (Q1, 2024)
$54.9M
EBIT (Q1, 2024)
($14.8M)
Enterprise value
$19.9M

Footer menu